Citations

Clear

948 citation(s) found for "Li, Bryan".

PPARγ Staining as a Surrogate for PAX8/PPARγ Fusion Oncogene Expression in Follicular Neoplasms: Clinicopathological Correlation and Histopathological Diagnostic Value
Şahi̇n, Mustafa , Allard, Brandon L., Yates, Martin T. , Powell, J. Gregory, Wang, Xiao-Li, Zhao, Ying , Goellner, John R., Sebo, Thomas J., Grebe, Stefan K., Eberhardt, Norman L., McIver, Bryan, Wang, Xiao-Li, Hay, Ian

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | January 10, 2005 | Volume: 90 | Issue: 1 | Pages: 463-468

10.1210/jc.2004-1203 | PMID 15483076 Get It

Abstract The PAX8/PPARγ (PPFP) fusion-oncogene is moderately specific for follicular thyroid carcinomas (FTC). It remains unknown whether this can be translated into improved diagnosis, classification, or outcome prediction. We studied a cohort of well-characterized follicular adenomas (FA), FTC, and Hürthle cell carcinomas (HCC) from patients with complete clinical follow-up, to determine whether PPARγ immunohistochemistry (as a surrogate of PAX8/PPARγ expression) helps to distinguish FA from FTC and to assess its diagnostic accuracy as an adjunct to frozen section. We also correlated PPARγ staining with clinical outcomes to assess its role as a prognostic marker. PPARγ staining was more common in FTC (31 of 54; 57%) than in HCC (one of 23; 4%) or FA (four of 31; 13%) (P < 0.000001). Adjunctive use of PPARγ immunohistochemistry improved diagnostic sensitivity of intraoperative frozen section from 84% to 96% (P < 0.05) but reduced specificity from 100% to 90% (P < 0.05). PPARγ staining was associated with favorable prognostic indicators (female gender, better tumor differentiation, and lesser risk of metastases). PPARγ staining may be helpful in the differential diagnosis of FA, FTC, and HCC, particularly when diagnostic sensitivity of histomorphology is reduced (e.g. during intraoperative frozen section). PPARγ staining also shows an association with favorable prognosis and may have a role in risk stratification.
COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code
Matteson, Jeanne, Moyer, Bryan D. , Yoo, Jin-San, Bannykh, Sergei I. , Wilson, Ian A. , Riordan, John R., An, Yu , Balch, William E.

Mayo Clinic

The Journal of Cell Biology | October 12, 2004 | Volume: 167 | Issue: 1 | Pages: 65-74

10.1083/jcb.200401035 | PMID 15479737 Get It

Cystic fibrosis (CF) is a childhood hereditary disease in which the most common mutant form of the CF transmembrane conductance regulator (CFTR) ΔF508 fails to exit the endoplasmic reticulum (ER). Export of wild-type CFTR from the ER requires the coat complex II (COPII) machinery, as it is sensitive to Sar1 mutants that disrupt normal coat assembly and disassembly. In contrast, COPII is not used to deliver CFTR to ER-associated degradation. We find that exit of wild-type CFTR from the ER is blocked by mutation of a consensus di-acidic ER exit motif present in the first nucleotide binding domain. Mutation of the code disrupts interaction with the COPII coat selection complex Sec23/Sec24. We propose that the di-acidic exit code plays a key role in linking CFTR to the COPII coat machinery and is the primary defect responsible for CF in ΔF508-expressing patients.
A novel dynamin III isoform is up-regulated in the central nervous system in hypothyroidism
Arnold, Andrew , Anderson, Grant W., McIver, Bryan, Eberhardt, Norman L.

Mayo Clinic

International Journal of Developmental Neuroscience | June 30, 2003 | Volume: 21 | Issue: 5 | Pages: 267-275

10.1016/s0736-5748(03)00053-4 | PMID 12850060 Get It

Additional Radiation Absorbed Dose Estimates for Zevalin™ Radioimmunotherapy
Wiseman, Gregory A., Leigh, Bryan R., Dunn, William L., Stabin, Michael G. , White, Christine A.

Mayo Clinic

Cancer Biotherapy and Radiopharmaceuticals | May 21, 2003 | Volume: 18 | Issue: 2 | Pages: 253-258

10.1089/108497803765036436 | PMID 12804052 Get It

Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia
Wiseman, Gregory A., Leigh, Bryan R., Erwin, William D. , Sparks, Richard, Podoloff, Donald A., Schilder, Russell J., Spies, Stewart, Grillo-López, Antonio J, White, Christine A., Bartlett, Nancy L. , Witzig, Thomas E.

Mayo Clinic

Cancer Biotherapy and Radiopharmaceuticals | May 21, 2003 | Volume: 18 | Issue: 2 | Pages: 165-178

10.1089/108497803765036337 | PMID 12804042 Get It

Rosai-Dorfman Disease of the Thyroid Masquerading as Anaplastic Carcinoma
Powell, J. Gregory, Goellner, John R., Nowak, Lynne E., McIver, Bryan

Mayo Clinic

Thyroid | April 16, 2003 | Volume: 13 | Issue: 2 | Pages: 217-221

10.1089/105072503321319549 | PMID 12699598 Get It

Long-term prognosis of children with papillary thyroid cancer presenting with pulmonary metastases
Brink, Jeromy, Heerden, Jon van, Farley, David R. , McIver, Bryan, Thompson, Geoffrey B. , Grant, Clive S., Zimmerman, Donald

Mayo Clinic

Journal of British Surgery | March 11, 2003 | Volume: 87 | Issue: 9 | Pages: 1277-1278

10.1046/j.1365-2168.2000.01601-50.x Get It

Abstract Background Papillary thyroid cancer (PTC) has a generally favourable prognosis, but elderly patients with distant metastases or extracapsular invasion fair poorly. In small studies with short follow-up, young patients presenting with such extracapsular invasion and pulmonary metastases have faired well. This retrospective study was undertaken to clarify the long-term prognosis of such patients with advanced PTC. Methods Twenty-one children and young adults (median age 14 (range 6–20) years) presenting with PTC and pulmonary metastases were treated at a single institution between 1947 and 1998. Mean maximal tumour diameter was 4·65 cm. Initial surgical treatment consisted of total thyroidectomy (n = 16), subtotal thyroidectomy (n = 4) and isthmectomy (n = 1), coupled with a variety of lymph node dissections (n = 20). After operation, 19 patients were treated with ablative and incremental doses of iodine-131 until disease free. All patients were placed on suppressive thyroid hormone after operation. Mean length of follow-up was 21 years (range 3 months to 47 years). Follow-up was less than 3 years in four patients. All patients have undergone post-treatment radionucleotide and radiological evaluation. Results Nine of the 21 patients developed recurrent disease. The risk of recurrence at 5 years was 39 (95 per cent confidence interval 14–57) per cent. Eight had cervical lymph node recurrence and no patient developed recurrent pulmonary disease. All patients with identifiable recurrent disease underwent selective lymph node resection, which involved multiple resections in four. At follow-up, 18 patients remain completely free of disease, one patient has recurrent cervical node disease and two patients have died. The disease-free survival at 5 years was 95 (95 per cent confidence interval 86–100) per cent. Cause-specific death occurred in a single patient who died from extensive local disease at age 29 years after 12 years of multiple cervical lymph node recurrences. Conclusion A stepwise treatment approach including total thyroidectomy, high-dose iodine-131 treatment and early surgical reintervention for suspected local recurrent disease allows long-term survival and frequent ‘cure’ for young patients with PTC and concomitant pulmonary metastases.
Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long‐term Outcome in 2444 Consecutively Treated Patients
Thompson, Geoffrey B. , Grant, Clive S., Bergstralh, Eric J., Dvorak, Catherine E., Gorman, Colum A., Maurer, Megan S., McIver, Bryan, Mullan, Brian P., Oberg, Ann L. , Powell, Claudia C., Heerden, Jon A. van, Goellner, John R., Hay, Ian

Mayo Clinic

World Journal of Surgery | October 14, 2002 | Volume: 26 | Issue: 8 | Pages: 879-885

10.1007/s00268-002-6612-1 | PMID 12016468 Get It

It is uncertain whether more extensive primary surgery and increasing use of radioiodine remnant ablation (RRA) for papillary thyroid carcinoma (PTC) have resulted in improved rates of cause‐specific mortality (CSM) and tumor recurrence (TR). Details of the initial presentation, therapy, and outcome of 2444 PTC patients consecutively treated during 1940–1999 were recorded in a computerized database. Patients were followed for more than 43,000 patient‐years. The 25‐year rates for CSM and TR were 5% and 14%, respectively. Temporal trends were analyzed for six decades. During the six decades, the proportion with initial MACIS (distant Metastasis, patient Age, Completeness of resection, local Invasion, and tumor Size) scores <6 were 77%, 82%, 84%, 86%, 85%, and 82%, respectively (p = 0.06). Lobectomy accounted for 70% of initial procedures during 1940–1949 and 22% during 1950–1959; during 1960–1999 bilateral lobar resection (BLR) accounted for 91% of surgeries (p <0.001). RRA after BLR was performed during 1950–1969 in 3% but increased to 18%, 57%, and 46% in successive decades (p <0.001). The 40‐year rates for CSM and TR during 1940–1949 were significantly higher (p = 0.002) than during 1950–1999. During the last 50 years the 10‐year CSM and TR rates for the 2286 cases did not significantly change with successive decades. Moreover, the 10‐year rates for CSM and TR were not significantly improved during the last five decades of the study, either for the 1917 MACIS <6 patients or the 369 MACIS ? 6 patients. Increasing use of RRA has not apparently improved the already excellent outcome, achieved before 1970, in low risk (MACIS <6) PTC patients managed by near‐total thyroidectomy and conservative nodal excision.